BD FACSDuet™ Premium System Leverages Robotics to Automate Sample Preparation for Greater Standardization in Clinical Flow Cytometry Diagnostics FRANKLIN LAKES, N.J. , June 12, 2023 /PRNewswire/ — BD ( Becton, Dickinson and Company ) (NYSE: BDX), a leading global medical technology company, Read more
BD FACSDiscover™ S8 Cell Sorter First to Combine Spectral Flow Cytometry with Real-Time Imaging Technology FRANKLIN LAKES, N.J. , May 18, 2023 /PRNewswire/ — BD ( Becton, Dickinson and Company ) (NYSE: BDX), a leading global medical technology company, announced the worldwide commercial launch of Read more
BD FACSDiscover™ S8 Cell Sorter with BD CellView™ Image Technology First to Combine Spectral Flow Cytometry with Sort-Capable Imaging FRANKLIN LAKES, N.J., June 3, 2022 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it will introduce new cell sorting technology at the International Society for Advancement... Read more
Revenue of $5.0 billion increased 2.1% as reported and 3.9% on currency-neutral basis Revenue driven by base revenue growth of 8.2% as reported, 10.2% currency-neutral, partially offset by decline in worldwide COVID-only testing revenues to $214 million from $474 million in the prior year GAAP diluted EPS of $1.50; adjusted diluted EPS of $3.18 Company... Read more
Developed with novel dye technology and AI guidance, new BD Horizon RealYellow™ 586 Reagents have potential to accelerate discovery and drug development in oncology, autoimmune disorders and infectious diseases FRANKLIN LAKES, N.J., April 25, 2022 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of... Read more
FRANKLIN LAKES, N.J., March 31, 2022 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Alberto Mas has informed the company of his intent to retire from BD, effective at the end of the company’s fiscal year on Sept. 30, 2022. Mas, 60, is currently executive... Read more
FRANKLIN LAKES, N.J., Feb. 3, 2022 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its first quarter of fiscal year 2022, which ended December 31, 2021. “Our first quarter results reflect continued execution of our BD2025 strategy and strong base business performance from all three segments.... Read more
FRANKLIN LAKES, N.J., Feb. 1, 2022 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has completed the acquisition of Cytognos, a privately held company headquartered in Salamanca, Spain, specializing in flow cytometry solutions for blood cancer diagnosis, minimal residual disease (MRD) detection and immune monitoring... Read more
FRANKLIN LAKES, N.J., Jan. 20, 2022 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that a study conducted in collaboration with the European Molecular Biology Laboratory (EMBL) and published as the cover story of the January 21st issue of the journal, Science, profiles a new BD... Read more
FRANKLIN LAKES, N.J., Nov. 4, 2021 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for the fourth fiscal quarter and full fiscal year ended September 30, 2021. “Our strong performance in fiscal 2021 was driven by the extraordinary efforts of our global team and demonstrates the resilience... Read more